pd 135158 has been researched along with Substance Withdrawal Syndrome in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Little, HJ; Wilson, J | 1 |
| Little, HJ; Watson, WP; Wilson, J | 1 |
| Costall, B; Domeney, AM; Hughes, J; Kelly, ME; Naylor, RJ; Woodruff, GN | 1 |
3 other study(ies) available for pd 135158 and Substance Withdrawal Syndrome
| Article | Year |
|---|---|
CCK(B) antagonists protect against some aspects of the ethanol withdrawal syndrome.
Topics: Acoustic Stimulation; Alcoholism; Animals; Anti-Anxiety Agents; Behavior, Animal; Central Nervous System Depressants; Dipeptides; Ethanol; Excitatory Amino Acid Agonists; Handling, Psychological; Indoles; Male; Meglumine; Mice; Mice, Inbred Strains; N-Methylaspartate; Receptors, Cholecystokinin; Seizures; Substance Withdrawal Syndrome | 1998 |
CCK(B) antagonists protect against anxiety-related behaviour produced by ethanol withdrawal, measured using the elevated plus maze.
Topics: Animals; Anxiety; Dipeptides; Ethanol; Indoles; Male; Maze Learning; Meglumine; Mice; Motor Activity; Rats; Rats, Wistar; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Receptors, Serotonin; Substance Withdrawal Syndrome | 1998 |
Anxiolytic effects of CCK-B antagonists.
Topics: Animals; Anti-Anxiety Agents; Behavior, Animal; Callitrichinae; Diazepam; Indoles; Meglumine; Mice; Rats; Receptors, Cholecystokinin; Substance Withdrawal Syndrome | 1991 |